Market Tracker

10/31 7:05pm ET

SPDR® S&P Biotech ETF (XBI)

During the Trading Day
171.39 -1.98 / -1.14%
Data as of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
171.33 -0.06 / -0.04%
 
Volume: 100.00

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

Performance

1 month+11.24% 3 years+37.42%
3 months+15.24% 5 years+30.36%
1 year+45.50% Since inception+15.78%
Data through 10/31/2014

Quote Details

Previous close$173.37
Open day’s range171.00 – 177.48
Net asset value (NAV)173.30 (10/30/2014)
Daily volume670,260
Average volume (3 months)389,582
Data as of 3:59pm ET, 10/31/2014

Peer Comparisonvs. Health ETFs

 XBICategory
Performance 5-yr return+30.36%+21.83%
Expense Gross exp ratio0.35%0.42%
Risk 5 year sharpe ratio0.971.39
Net assets$1.2B$1.5B
Average market cap$2.0B$27.2B
Average P/E--29.1
Dividend / Share--0.20%

Competitors

XLV Health Care Select Sector SPDR® Fund
VHT Vanguard Health Care Index Fund ETF Shar...
RYH Guggenheim S&P 500® Equal Weight Health...

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
AGIO Agios Pharmaceuticals Inc1.85%
PTCT PTC Therapeutics Inc1.79%
AMAG AMAG Pharmaceuticals Inc1.64%
MACK Merrimack Pharmaceuticals Inc1.61%
VRTX Vertex Pharmaceuticals Inc1.61%
ACOR Acorda Therapeutics Inc1.48%
ALNY Alnylam Pharmaceuticals Inc1.43%
RGEN Repligen Corp1.42%
BMRN Biomarin Pharmaceutical Inc1.41%
MYGN Myriad Genetics Inc1.40%